Ionis Pharmaceuticals, which recently announced it will open a sprawling research-and-development center in Oceanside, also plans a large expansion of its home base in Carlsbad.
The potential next pathway to target in CVD prevention: ‘Common’ elevated Lp(a)
About 20% of the global population and one in five U.S. adults have elevated levels of lipoprotein(a), a complex form of LDL that strongly predicts risk for coronary disease and aortic valve stenosis. Evidence for a causal association between Lp(a) concentration, which is primarily genetically determined, and CV outcomes across ethnicities continues to build.
After blazing trails in RNA-targeted drugs, Ionis jumps into gene editing
Ionis Pharmaceuticals, the California company that turned RNA-targeting medicines from an unproven idea into blockbuster drugs, is now expanding into a new class of therapeutics that treat disease by editing DNA.
Ionis teams with Metagenomi and dives into gene editing
Ionis Pharmaceuticals has formed an alliance with gene editing startup Metagenomi in a bid to branch out beyond the RNA-based drugs it’s known for.